Analysis of pharmaceutical care in patients with psoriatic arthritis using statutory health insurance data

Analysis of pharmaceutical care in patients with psoriatic arthritis using statutory health... IntroductionPsoriatic arthritis (PsA) – a spondyloarthropathy – is a heterogeneous and potentially severe rheumatic disease. While PsA can occur at any age, its usual age of onset is between the ages of 35 and 45 ; more than 20 % of psoriasis patients in Germany are thought to be affected . Overall, 0.1–1 % of the population have some form of PsA . In approximately 70 % of cases, joint involvement is preceded by cutaneous manifestations. However, the latter may also develop simultaneously (approximately 15 %), at a later point in time (approximately 10 %), or not at all (5 %) .Clinically, PsA is characterized by rheumatoid factor‐­negative oligo‐ or polyarthritis, enthesitis (inflammation of tendon insertions), dactylitis (inflammation of an entire toe or finger), and/or spondylitis. Roughly 3–5 % of PsA patients develop mutilating arthritis, a destructive disease variant .Correct and early diagnosis paramount as regards the progression of PsA; however, given the heterogeneous nature of the disease, establishing the diagnosis poses a challenge to the various medical specialties involved . The interval between initial disease manifestations and confirmation of the diagnosis is, on average, five years . Evidence of an active inflammatory musculoskeletal disease is a crucial step in diagnosing PsA. Since 2006, the Classification http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal Der Deutschen Dermatologischen Gesellschaft Wiley

Analysis of pharmaceutical care in patients with psoriatic arthritis using statutory health insurance data

Loading next page...
 
/lp/wiley/analysis-of-pharmaceutical-care-in-patients-with-psoriatic-arthritis-G5Q96RIcRZ
Publisher
Wiley
Copyright
© 2018 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.
ISSN
1610-0379
eISSN
1610-0387
D.O.I.
10.1111/ddg.13464
Publisher site
See Article on Publisher Site

Abstract

IntroductionPsoriatic arthritis (PsA) – a spondyloarthropathy – is a heterogeneous and potentially severe rheumatic disease. While PsA can occur at any age, its usual age of onset is between the ages of 35 and 45 ; more than 20 % of psoriasis patients in Germany are thought to be affected . Overall, 0.1–1 % of the population have some form of PsA . In approximately 70 % of cases, joint involvement is preceded by cutaneous manifestations. However, the latter may also develop simultaneously (approximately 15 %), at a later point in time (approximately 10 %), or not at all (5 %) .Clinically, PsA is characterized by rheumatoid factor‐­negative oligo‐ or polyarthritis, enthesitis (inflammation of tendon insertions), dactylitis (inflammation of an entire toe or finger), and/or spondylitis. Roughly 3–5 % of PsA patients develop mutilating arthritis, a destructive disease variant .Correct and early diagnosis paramount as regards the progression of PsA; however, given the heterogeneous nature of the disease, establishing the diagnosis poses a challenge to the various medical specialties involved . The interval between initial disease manifestations and confirmation of the diagnosis is, on average, five years . Evidence of an active inflammatory musculoskeletal disease is a crucial step in diagnosing PsA. Since 2006, the Classification

Journal

Journal Der Deutschen Dermatologischen GesellschaftWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off